We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WST icon
76
West Pharmaceutical
WST
$24.9B
$594K 0.13%
+1,500
New +$555K
INDV icon
77
Indivior Pharmaceuticals
INDV
$4.58B
$591K 0.13%
27,601
+3,500
+15% +$65.7K
RYTM icon
78
Rhythm Pharmaceuticals
RYTM
$7.96B
$537K 0.12%
+12,400
New +$543K
TMTC
79
DELISTED
TMT Acquisition Corp Ordinary Shares
TMTC
$535K 0.12%
50,000
– –
JANX icon
80
Janux Therapeutics
JANX
$967M
$527K 0.12%
+14,000
New +$305K
NRIX icon
81
Nurix Therapeutics
NRIX
$2.65B
$523K 0.12%
+35,608
New +$383K
YEAR icon
82
AB Ultra Short Income ETF
YEAR
$1.51B
$505K 0.11%
10,000
– –
STVN icon
83
Stevanato
STVN
$5.54B
$498K 0.11%
+15,500
New +$472K
PULS icon
84
PGIM Ultra Short Bond ETF
PULS
$18.3B
$497K 0.11%
10,000
– –
VTGN icon
85
VistaGen Therapeutics
VTGN
$12.8M
$475K 0.11%
89,938
-155,564
-63% -$748K
JBIO
86
Jade Biosciences
JBIO
$1.34B
$470K 0.11%
+454
New +$347K
TYRA icon
87
Tyra Biosciences
TYRA
$1.58B
$464K 0.11%
+28,300
New +$464K
ARYD
88
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$460K 0.1%
+40,930
New +$457K
EQ icon
89
Equillium
EQ
$133M
$459K 0.1%
198,775
+192,275
+2,958% +$334K
INBS icon
90
Intelligent Bio Solutions
INBS
$4.74M
$457K 0.1%
+10,825
New +$448K
CBIO
91
PUT
Crescent Biopharma
CBIO
$626M
$417K 0.09%
+1,391
New +$415K
APGE icon
92
Apogee Therapeutics
APGE
$10.2B
$399K 0.09%
+6,000
New +$262K
MIST icon
93
Milestone Pharmaceuticals
MIST
$152M
$362K 0.08%
+202,460
New +$329K
BCYC
94
Bicycle Therapeutics
BCYC
$292M
$359K 0.08%
14,430
-60,395
-81% -$1.28M
ZLAB icon
95
Zai Lab
ZLAB
$2.62B
$352K 0.08%
22,000
+2,000
+10% +$42.1K
GH icon
96
Guardant Health
GH
$22.6B
$351K 0.08%
+17,000
New +$364K
YARW
97
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$338K 0.08%
+2,202
New +$237K
CTMX icon
98
CytomX Therapeutics
CTMX
$754M
$338K 0.08%
+155,000
New +$286K
OAKU
99
DELISTED
Oak Woods Acquisition Corp
OAKU
$323K 0.07%
30,000
– –
SCRM
100
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
$321K 0.07%
30,000
– –
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.